Problems related to acid rebound and tachyphylaxis

Acid regulation in the stomach is a topic of ongoing clinical interest. Histamine H2-receptor antagonists have been known to cause rebound acid hypersecretion. This effect has been observed in response to meals and gastrin-releasing peptide. It does not occur during peak pentagastrin stimulation. The phenomenon appears by day three of treatment and resolves by day ten. A recent study in healthy volunteers suggests clinical relevance. Tolerance to H2-antagonists is also established. It involves a decline in acid inhibition efficacy. This occurs within a few doses but does not worsen after 29 days of use.

The study aimed to clarify the mechanisms and clinical implications of acid rebound and tachyphylaxis. These phenomena are observed with H2-antagonists and proton pump inhibitors. The goal was to assess how acid suppression affects gastric physiology. Researchers focused on the duration and triggers of rebound acid secretion. They also examined the onset and progression of drug tolerance. The study considered both short- and long-term effects of these drugs. Clinical relevance was a key focus, especially in asymptomatic individuals. The findings could inform treatment guidelines for acid-related disorders.

The study used a combination of clinical trials and pharmacological analysis. Researchers monitored gastric acid output in healthy volunteers. They measured basal and maximal acid secretion after drug cessation. Histamine H2-antagonists and proton pump inhibitors were tested separately. Gastrin-releasing peptide and pentagastrin were used as stimulants. Helicobacter pylori status was assessed in proton pump inhibitor studies. The duration of rebound acid hypersecretion was tracked over two months. Tolerance was evaluated through repeated dosing and efficacy monitoring.

Rebound acid hypersecretion was observed after H2-antagonists within three days. It resolved by ten days but was absent during peak pentagastrin stimulation. Tolerance to H2-antagonists occurred within a few doses but did not progress. Proton pump inhibitors caused prolonged rebound acid secretion lasting at least two months. This effect was seen in Helicobacter pylori-negative subjects only. Hypergastrinaemia due to acid suppression likely explains this. Gastric mucosal changes were linked to the duration of proton pump inhibitor use. No evidence of tachyphylaxis was found in proton pump inhibitor studies.

The authors suggest that rebound acid hypersecretion is a class effect of H2-antagonists. It may have clinical relevance in asymptomatic individuals. Tolerance to H2-antagonists is rapid but not progressive. Proton pump inhibitors cause prolonged acid rebound. This is likely due to gastric mucosal changes from acid suppression. The effect is limited to Helicobacter pylori-negative patients. Tachyphylaxis with proton pump inhibitors remains unconfirmed. Long-term studies may be needed to clarify clinical implications.